
News|Articles|April 1, 2009
FDA Pipeline preview, April 2009 (alglucosidase alfa, bosentan, cetuximab, doxepin, telavancin, quetiapine extended-release, oxycodone/niacin, EUR-1073)
Recent FDA action (through April 2009) related to alglucosidase alfa, bosentan, cetuximab, doxepin, telavancin, quetiapine extended-release, oxycodone/niacin, and EUR-1073
Advertisement
Complete response
Priority review
Orphan drug designations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Journavx helped most patients avoid opioids after surgery, a recent study found
2
Cholinergic urticaria: Hives caused by heat and what can be done about it
3
A conversation with Julia S. Feldman, Ph.D., about taking impairment and context into consideration when diagnosing preschoolers with ADHD
4
The biosimilars market is projected to nearly double — here's where the growth is coming from
5















